Welcome to Hodoodo Chemicals

Diatrizoate sodium
featured

WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H461144

CAS#: 737-31-5 (sodium)

Description: Diatrizoate Sodium is an X-ray contrast agent. Diatrizoate sodium blocks X-rays which lets body structures with iodine to be delineated in comparison to the structures that do not have iodine. This is used as a diagnostic aid in angiography, urography and radiography.

Chemical Structure

Diatrizoate sodium

CAS# 737-31-5 (sodium)

Instruction

Theoretical Analysis

Hodoodo Cat#: H461144
Name: Diatrizoate sodium
CAS#: 737-31-5 (sodium)
Chemical Formula: C11H8I3N2NaO4
Exact Mass: 0.00
Molecular Weight: 635.890
Elemental Analysis: C, 20.78; H, 1.27; I, 59.87; N, 4.41; Na, 3.62; O, 10.06

Price and Availability

Size	Price	Availability
5g	USD 250	2 Weeks
10g	USD 400	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. Hodoodo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Diatrizoate sodium; Hypaque; MD-50; MD 50; MD50; Triombrin; Urovist Sodium;

IUPAC/Chemical Name: sodium 3,5-diacetamido-2,4,6-triiodobenzoate

InChi Key: ZEYOIOAKZLALAP-UHFFFAOYSA-M

InChi Code: InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1

SMILES Code: CC(Nc1c(I)c(C([O-])=O)c(I)c(NC(C)=O)c1I)=O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 635.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Abd El-Rahman MK, Riad SM, Abdel Gawad SA, Fawaz EM, Shehata MA. Stability indicating spectrophotometric and spectrodensitometric methods for the determination of diatrizoate sodium in presence of its degradation product. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt B:1167-74. doi: 10.1016/j.saa.2014.10.002. Epub 2014 Oct 16. PubMed PMID: 25456658.

2: Riad SM, El-Rahman MKA, Fawaz EM, Shehata MA. A comparative study between three stability indicating spectrophotometric methods for the determination of diatrizoate sodium in presence of its cytotoxic degradation product based on two-wavelength selection. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Jun 15;145:254-259. doi: 10.1016/j.saa.2015.03.030. Epub 2015 Mar 9. PubMed PMID: 25791882.

3: Shafieyan Y, Khosravi N, Moeini M, Quinn TM. Diffusion of MRI and CT contrast agents in articular cartilage under static compression. Biophys J. 2014 Jul 15;107(2):485-492. doi: 10.1016/j.bpj.2014.04.041. PubMed PMID: 25028890; PubMed Central PMCID: PMC4104049.

4: Peterson CM, Lin M, Pilgram T, Heiken JP. Prospective randomized trial of iohexol 350 versus meglumine sodium diatrizoate as an oral contrast agent for abdominopelvic computed tomography. J Comput Assist Tomogr. 2011 Mar-Apr;35(2):202-5. doi: 10.1097/RCT.0b013e3182058e76. PubMed PMID: 21412090.

5: Hirasaki S, Murakami K, Mizushima T, Hiramatsu K, Hanayama Y, Kanamori T, Koide N. Long-term Taenia saginata infection successfully treated with meglumine/diatrizoate sodium. Intern Med. 2012;51(2):177-9. Epub 2012 Jan 15. PubMed PMID: 22246486.

6: McNamara MM, Lockhart ME, Fineberg NS, Berland LL. Oral contrast media for body CT: Comparison of diatrizoate sodium and iohexol for patient acceptance and bowel opacification. AJR Am J Roentgenol. 2010 Nov;195(5):1137-41. doi: 10.2214/AJR.09.3968. PubMed PMID: 20966319.

7: Frost AB, Larsen F, Larsen SW, Østergaard J, Thomsen MH, Stürup S, Andersen PH, Larsen C. The pharmacokinetics of the weakly protein-bound anionic compound diatrizoate in serum and synovial fluid of the horse. Pharm Res. 2010 Jan;27(1):143-50. doi: 10.1007/s11095-009-9988-x. Epub 2009 Oct 30. PubMed PMID: 19876722.

8: Frost AB, Larsen F, Ostergaard J, Larsen SW, Lindegaard C, Hansen HR, Larsen C. On the search for in vitro in vivo correlations in the field of intra-articular drug delivery: administration of sodium diatrizoate to the horse. Eur J Pharm Sci. 2010 Sep 11;41(1):10-5. doi: 10.1016/j.ejps.2010.05.006. Epub 2010 May 16. PubMed PMID: 20580670.

9: Jacobson ED, Eldon C, Fondacaro JD. Effects of a rapid injection into the canine superior mesenteric artery of diatrizoate meglumine and diatrizoate sodium (Renografin-76). Cardiovasc Intervent Radiol. 1980;3(3):159-62. PubMed PMID: 7407811.

10: DOEHNER GA, BRUGGER GE. Comparison of diatrizoate methylglucamine, sodium acetrizoate, and diatrizoate sodium in cerebral angiography. N Y State J Med. 1960 Dec 15;60:4022-4. PubMed PMID: 13723380.

11: Craver BN, Chinn C, Hess SM, Swoap JR. Penetration through the blood-brain barriers of cats after intracarotid injections of 125-I sodium diatrizoate, methylglucamine diatrizoate, or methylglucamine diatrizoate plus parabens and the retention of 131-I methylglucamine diatrizoate in the blood of rats. Radiology. 1968 Jan;90(1):142-6. PubMed PMID: 5635126.

12: Kadlec R, Jakubec M, Jaglic Z. A novel flotation technique for the separation of nonadherent micro-organisms from a substrate. Lett Appl Microbiol. 2014 Jun;58(6):604-9. doi: 10.1111/lam.12234. Epub 2014 Mar 11. PubMed PMID: 24527951.

13: Pollentine A, Ngan-Soo E, McCoubrie P. Acceptability of oral iodinated contrast media: a head-to-head comparison of four media. Br J Radiol. 2013 May;86(1025):20120636. doi: 10.1259/bjr.20120636. PubMed PMID: 23564884; PubMed Central PMCID: PMC3635798.

14: Bentley MD, Vanhoutte V, Schryver SM, Romero JC, Vanhoutte PM. Contraction of isolated canine renal arteries induced by the radiocontrast medium sodium diatrizoate and meglumine diatrizoate. J Lab Clin Med. 1987 May;109(5):595-600. PubMed PMID: 3572209.

15: Yaghmai V, Harapanhalli RS, Patel YD, Baker SR, Rao DV. Effects of diatrizoate and iopamidol on spermatogenesis. Invest Radiol. 1993 Dec;28(12):1160-4. PubMed PMID: 8307722.

16: Chellquist EM, Nelson WO, Storflor HL. Assay and purity analysis of diatrizoate sodium in drug product by LC. J Pharm Biomed Anal. 1997 Sep;16(1):39-45. PubMed PMID: 9447550.

17: Miller SH. Anaphylactoid reaction after oral administration of diatrizoate meglumine and diatrizoate sodium solution. AJR Am J Roentgenol. 1997 Apr;168(4):959-61. PubMed PMID: 9124149.

18: Michelassi PL, Rindi P, Pilone N, Simonetti F. [Investigation on the renal clearance of metylglucamine diatrizoate and of sodium and metylglucamine diatrizoate (author's transl)]. Radiol Med. 1979 Sep;65(9):611-4. Italian. PubMed PMID: 554248.

19: Fischer HW, Redman HC. Comparison of a sodium methylglucamine diatrizoate contrast medium of minimal sodium content with a pure methylglucamine diatrizoate preparation. Invest Radiol. 1971 Mar-Apr;6(2):115-8. PubMed PMID: 5157567.

20: Schmidt BJ, Foley WD, Bohorfoush AG. Toxic epidermal necrolysis related to oral administration of diluted diatrizoate meglumine and diatrizoate sodium. AJR Am J Roentgenol. 1998 Nov;171(5):1215-6. PubMed PMID: 9798850.